Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839,'Iressa') on an expanded access study

PA Jänne, S Gurubhagavatula, BY Yeap, J Lucca… - Lung cancer, 2004 - Elsevier
Purpose: To investigate the anti-tumor activity and toxicity of the epidermal growth factor
receptor (EGFR) inhibitor gefitinib (ZD1839 or Iressa™; AstraZeneca Pharmaceuticals …
被引用次数：261 相关文章

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839,'Iressa') on an expanded access study

PA Jänne, S Gurubhagavatula, BY Yeap, J Lucca… - Lung Cancer, 2004 - infona.pl
Purpose: To investigate the anti-tumor activity and toxicity of the epidermal growth factor
receptor (EGFR) inhibitor gefitinib (ZD1839 or Iressa (TM); AstraZeneca Pharmaceuticals …

[引用][C] Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839,'Iressa') on an expanded access study

PA JÄNNE, S GURUBHAGAVATULA, BY YEAP… - Lung …, 2004 - pascal-francis.inist.fr
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839,
'Iressa') on an expanded access study CNRS Inist Pascal-Francis CNRS Pascal and …

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839,'Iressa') on an expanded access study

PA Jänne, S Gurubhagavatula, BY Yeap… - Lung …, 2004 - lungcancerjournal.info
Purpose: To investigate the anti-tumor activity and toxicity of the epidermal growth factor
receptor (EGFR) inhibitor gefitinib (ZD1839 or Iressa™; AstraZeneca Pharmaceuticals …

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839," Iressa") on an expanded access study

PA Jänne, S Gurubhagavatula… - Lung cancer …, 2004 - pubmed.ncbi.nlm.nih.gov
Purpose To investigate the anti-tumor activity and toxicity of the epidermal growth factor
receptor (EGFR) inhibitor gefitinib (ZD1839 or Iressa; AstraZeneca Pharmaceuticals …

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839," Iressa") on an expanded access study.

PA Jänne, S Gurubhagavatula, BY Yeap… - Lung Cancer …, 2004 - europepmc.org
Purpose To investigate the anti-tumor activity and toxicity of the epidermal growth factor
receptor (EGFR) inhibitor gefitinib (ZD1839 or Iressa; AstraZeneca Pharmaceuticals …

[引用][C] Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839,'Iressa') on an expanded access study

PA JÄNNE, S GURUBHAGAVATULA, BY YEAP… - Lung cancer, 2004 - Elsevier